Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab for Cancer Pain Due to Bone Metastasis
NCT02609828Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2015
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in cancer pain, sponsored by Pfizer. Primary endpoint: Change From Baseline in the Daily Average Pain Intensity Numerical Rating Score (NRS) in the Index Bone Metastasis Cancer Pain Site at 8 weeks. Started Oct 2015; status: completed.
02
Drugs
tanezumab
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT02609828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609828.